BlackRock
PRLD icon

BlackRock’s Prelude Therapeutics PRLD Stock Holding History

BlackRock’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1M Buy
321,886
+55,606
+21% +$146K ﹤0.01% 4309
2025
Q4 		$772K Buy
266,280
+1,307
+0.5% +$2.21K ﹤0.01% 4380
2025
Q3 		$382K Sell
264,973
-167,586
-39% -$168K ﹤0.01% 4528
2025
Q2 		$350K Sell
432,559
-615,166
-59% -$533K ﹤0.01% 4525
2025
Q1 		$805K Sell
1,047,725
-22,048
-2% -$20.6K ﹤0.01% 4255
2024
Q4 		$1.36M Buy
1,069,773
+11,457
+1% +$15.2K ﹤0.01% 4145
2024
Q3 		$2.19M Sell
1,058,316
-10,600
-1% -$49.1K ﹤0.01% 3969
2024
Q2 		$4.07M Sell
1,068,916
-28,558
-3% -$116K ﹤0.01% 3761
2024
Q1 		$5.2M Buy
1,097,474
+1,885
+0.2% +$7.33K ﹤0.01% 3657
2023
Q4 		$4.68M Buy
1,095,589
+27,155
+3% +$82.7K ﹤0.01% 3717
2023
Q3 		$3.3M Buy
1,068,434
+209,313
+24% +$785K ﹤0.01% 3827
2023
Q2 		$3.87M Buy
859,121
+436,093
+103% +$2.61M ﹤0.01% 3814
2023
Q1 		$2.41M Buy
423,028
+29,475
+7% +$180K ﹤0.01% 3964
2022
Q4 		$2.38M Sell
393,553
-65,581
-14% -$420K ﹤0.01% 4067
2022
Q3 		$3.03M Sell
459,134
-70,301
-13% -$474K ﹤0.01% 3982
2022
Q2 		$2.76M Sell
529,435
-522,525
-50% -$2.66M ﹤0.01% 4095
2022
Q1 		$7.26M Buy
1,051,960
+155,456
+17% +$1.42M ﹤0.01% 3755
2021
Q4 		$11.2M Buy
896,504
+170,542
+23% +$2.77M ﹤0.01% 3608
2021
Q3 		$22.7M Buy
725,962
+23,120
+3% +$749K ﹤0.01% 3197
2021
Q2 		$20.1M Buy
702,842
+21,117
+3% +$752K ﹤0.01% 3305
2021
Q1 		$29.5M Buy
681,725
+44,592
+7% +$2.96M ﹤0.01% 2959
2020
Q4 		$45.6M Buy
637,133
+574,683
+920% +$28.6M ﹤0.01% 2531
2020
Q3 		$1.88M Buy
+62,450
New +$1.76M ﹤0.01% 3922

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock's PRLD Position: Q1 2026 in Review

BlackRock increased its Prelude Therapeutics (PRLD) stake by 21% in Q1 2026, buying an estimated $146K and bringing the position to 321,886 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #4309.

BlackRock first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $45.6M in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • BlackRock held 321,886 shares of Prelude Therapeutics worth $1.1M as of Q1 2026.
  • BlackRock bought 55,606 Prelude Therapeutics shares in Q1 2026, an estimated $146K.
  • Prelude Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4309 holding.
  • BlackRock first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • BlackRock's Prelude Therapeutics position peaked at $45.6M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.